A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

In any case, the present analysis was still limited by the lack of accounting for variables such as the different types and doses of GLP-1 agonists used, the difference between a surgery versus ...

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

A study in Nature noted that GLP-1 agonists can decrease inflammation in brain tissue, which is crucial since chronic inflammation is linked to cognitive decline. Stable blood sugar levels are ...

The risk for kidney function decline is lower among new users of sodium glucose cotransporter-2 inhibitors (SGLT2i) vs glucagon-like peptide 1 receptor agonists (GLP-1RA), a real-world study of ...

Background: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have shown efficacy for reducing ... Objective: To compare risk of incident AF after initiation of GLP1-RA vs Dipeptidyl peptidase-4 ...

Background: GLP-1 receptor agonists (GLP1RA) agonists have been shown to reduce ... Compared to the control group, the GLP1RA cohort had a higher baseline risk profile (BMI: 35.1 [SD 7.6] vs. 31.0 [SD ...

For example, GLP-1 agonist users had significantly higher rates of obesity compared with the general type 1 population (69.4% vs 26.8%), while SGLT2 inhibitor users had higher proportions of ...

For patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and diabetes, treatment with a glucagon-like peptide 1 receptor agonist ... use (9.98 vs 11.1 events per ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer ... combines this drug with AZD6234, a long-acting analogue targeting the pancreas hormone amylin, which ...

The biotech said it would use the cash to “further accelerate” a portfolio led by its GLP-1 receptor agonist MET-097 ... an injectable amylin analog that is Metsera’s answer to the sector ...

Reduction seen in recurrent nephrolithiasis events for those receiving SGLT-2 inhibitors vs GLP-1 RAs ... an SGLT-2 inhibitor or glucagon-like peptide-1 receptor agonist (GLP-1 RA), with a ...